Skip to main content

Posts tagged with "Drug Development"

  • Drug Development

  • Academia (vs. Industry)

    Francis Collins Speaks

    With all the recent talk about the NIH’s translational research efforts, and the controversy about their drug screening efforts, this seems like a good time to note this interview with Francis Collins over at BioCentury TV. (It’s currently the lead video, but you’ll be able to find it in their “Show Guide” afterwards a… Read More
  • Drug Development

    A Note to Andy Grove

    Readers will recall my occasional pieces on Intel legend Andy Grove’s idea for drug discovery. (The first one wasn’t too complimentary; the second was a bit more neutral). You always wonder, when you have a blog, if the people you’re writing about have a chance to see what you’ve said – well, in this case… Read More
  • Drug Development

    Harvard to the Rescue

    Harvard is announcing a big initiative in systems biology, which is an interdisciplinary opportunity if there ever was one. The Initiative in Systems Pharmacology is a signature component of the HMS Program in Translational Science and Therapeutics. There are two broad goals: first, to increase significantly our knowledge of human disease mechanism… Read More
  • Cancer

    Too Many Cancer Drugs? Too Few? About Right?

    According to Bruce Booth (@LifeSciVC on Twitter), Ernst & Young have estimated the proportion of drugs in the clinic in the US that are targeting cancer. Anyone want to pause for a moment to make a mental estimate of their own? Well, I can tell you that I was a bit low. The E&Y number… Read More
  • Drug Assays

    Different Drug Companies Make Rather Different Compounds

    Now here’s a paper, packed to the edges with data, on what kinds of drug candidate compounds different companies produce. The authors assembled their list via the best method available to outsiders: they looked at what compounds are exemplified in patent filings What they find is that over the 2000-2010 period that not much change… Read More
  • Academia (vs. Industry)

    How Many New Drug Targets Aren’t Even Real?

    So, are half the interesting new results in the medical/biology/med-chem literature impossible to reproduce? I linked earlier this year to an informal estimate from venture capitalist Bruce Booth, who said that this was his (and others’) experience in the business. Now comes a new study from Bayer Pharmaceuticals that helps put some backing b… Read More
  • Drug Development

    GlaxoSmithKline Reviews the Troops

    Several readers sent along this article from the Times of London (via the Ottawa Citizen) on GlaxoSmithKline’s current research setup. You can tell that the company is trying to get press for this effort, because otherwise these are the sorts of internal arrangements that would never be in the newspapers. (The direct quotes from the… Read More
  • Business and Markets

    Chinese Pharma: No Shortage of Ambition, Anyway

    When does China take the next step in drug research? They already have a huge contract research industry, and they have branches of many of the major pharma companies. But when does a Chinese startup, doing its own research with its own people in China, develop its own international-level drug pipeline? (We’ll leave aside the… Read More
  • Alzheimer's Disease

    Bernard Munos Rides Again

    I’ve been meaning to link to Matthew Herper’s piece on Bernard Munos and his ideas on what’s wrong with the drug business. Readers will recall several long discussions here about Munos and his published thoughts (Parts one, two, three and four). A take-home message: So how can companies avoid tossing away billions on medicines tha… Read More